BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19656883)

  • 1. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys.
    Sun Y; Bailer RT; Rao SS; Mascola JR; Nabel GJ; Koup RA; Letvin NL
    J Virol; 2009 Oct; 83(20):10596-604. PubMed ID: 19656883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
    Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH
    J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.
    Sun Y; Santra S; Buzby AP; Mascola JR; Nabel GJ; Letvin NL
    Virology; 2010 Oct; 406(1):48-55. PubMed ID: 20667574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.
    Cayabyab MJ; Korioth-Schmitz B; Sun Y; Carville A; Balachandran H; Miura A; Carlson KR; Buzby AP; Haynes BF; Jacobs WR; Letvin NL
    J Virol; 2009 Jun; 83(11):5505-13. PubMed ID: 19297477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.
    Barratt-Boyes SM; Soloff AC; Gao W; Nwanegbo E; Liu X; Rajakumar PA; Brown KN; Robbins PD; Murphey-Corb M; Day RD; Gambotto A
    J Gen Virol; 2006 Jan; 87(Pt 1):139-149. PubMed ID: 16361426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.
    Bolton DL; Santra S; Swett-Tapia C; Custers J; Song K; Balachandran H; Mach L; Naim H; Kozlowski PA; Lifton M; Goudsmit J; Letvin N; Roederer M; Radošević K
    Vaccine; 2012 Sep; 30(41):5991-8. PubMed ID: 22732429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.
    Masek-Hammerman K; Li H; Liu J; Abbink P; La Porte A; O'Brien KL; Whitney JB; Carville A; Mansfield KG; Barouch DH
    J Virol; 2010 Oct; 84(19):9810-6. PubMed ID: 20686023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
    Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
    J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
    Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
    J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
    Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys.
    Li H; Liu J; Carville A; Mansfield KG; Lynch D; Barouch DH
    J Virol; 2011 Nov; 85(21):11007-15. PubMed ID: 21917969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
    Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
    PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
    Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
    J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
    Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
    J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.
    Schulte R; Suh YS; Sauermann U; Ochieng W; Sopper S; Kim KS; Ahn SS; Park KS; Stolte-Leeb N; Hunsmann G; Sung YC; Stahl-Hennig C
    Virology; 2009 Jan; 383(2):300-9. PubMed ID: 19027133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.